Skip to content
Clinical Trials – home

AGE Centrum s.r.o.

Verified siteinfo

Czechia Na Sibeniku 914/1 Nova Ulice, 779 00 Olomouc, Czechia

  • 3 trials recruiting
  • Dementia Alzheimer's type · Dermatitis atopic · Rheumatoid arthritis
  • Adults and children

About Specializations

AGE Centrum s.r.o. in Olomouc, Czechia specialises in clinical trials of conditions such as Dementia Alzheimer's type, Dermatitis atopic, Rheumatoid arthritis, Dementia of the Alzheimer's type uncomplicated, and other specialisations. This site conducts important research.

Main research areas of the site

Neurology and Psychiatry

The AGE Centrum s.r.o. site in Olomouc is conducting clinical research in nervous system diseases and mental disorders, with a strong focus on Alzheimer’s disease and related cognitive and behavioral symptoms. These studies are designed to evaluate new approaches for improving memory, thinking, function, and agitation control in people living with mild cognitive impairment, mild to moderate Alzheimer’s disease, and agitation associated with Alzheimer’s disease.

  • Testing therapies aimed at improving cognition and daily function in early Alzheimer’s disease
  • Evaluating treatments for agitation and behavioral symptoms linked to Alzheimer’s disease
  • Studying options for people with biomarker evidence of inflammation in early neurodegenerative disease

Overall, this research area combines symptom management with efforts to slow or improve disease-related decline, offering potential benefit for both patients and caregivers.

Immunology and Skin Disease

Clinical trials at AGE Centrum s.r.o. also cover immune system diseases and skin and connective tissue diseases, especially atopic dermatitis. The studies are centered on reducing inflammation, improving skin symptoms, and maintaining treatment response over time in people with moderate-to-severe disease.

  • Assessing long-term safety and effectiveness of new therapies for atopic dermatitis
  • Comparing active treatment with placebo to better understand symptom control
  • Exploring ways to maintain response after initial improvement in chronic skin inflammation

This research supports the development of better options for people whose skin disease remains difficult to control with standard care.

Rheumatology and Inflammatory Disease

The site is involved in musculoskeletal diseases research, with a clear emphasis on rheumatoid arthritis. These trials are focused on easing joint inflammation, improving disease activity, and finding more effective treatment strategies for people who have not responded well to prior therapies or who are newly diagnosed.

  • Evaluating new anti-inflammatory treatments for moderate to severe rheumatoid arthritis
  • Studying treatment combinations for early disease control in newly diagnosed patients
  • Comparing investigational approaches with placebo or standard therapy to measure symptom improvement

By addressing both early and more established disease, this research aims to refine care for patients living with chronic inflammatory joint conditions.

Gastroenterology

Research at AGE Centrum s.r.o. includes digestive system diseases, particularly ulcerative colitis. The trial activity in this area is centered on achieving clinical remission and improving control of intestinal inflammation in people with active disease.

  • Assessing whether treatment can help patients reach remission more effectively
  • Measuring improvement in bowel symptoms and endoscopic signs of inflammation
  • Supporting the search for better options for patients with persistent inflammatory bowel disease

This work reflects an ongoing effort to improve both symptom relief and disease control in chronic gastrointestinal inflammation.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Na Sibeniku 914/1 Nova Ulice779 00 OlomoucCzechia
Recruiting now
3 trials
Conditions studied
5
Partner status
Verified site

More sites in OlomoucCzechia

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

12 clinical trials

A study testing xanomeline tartrate and trospium chloride for treating agitation in patients with Alzheimer's disease

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of trospium chloride and xanomeline tartrate combination for agitation in Alzheimer's disease patients: Long-term safety evaluation

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of xanomeline tartrate and trospium chloride combination for cognitive impairment in people with mild to moderate Alzheimer's disease

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Rheumatoid arthritis

Not recruiting

Study on the Effects of AP1189 and Methotrexate for Patients with Early Rheumatoid Arthritis and Active Inflammation

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Methotrexate
  • Sponsor:Synact Pharma ApS

Study on the Effects of Semaglutide in Patients with Early Alzheimer's Disease

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Dermatitis atopic

Not recruiting

Study on Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Dermatitis atopic

Not recruiting

Study on Long-Term Safety and Efficacy of Amlitelimab for Patients with Moderate to Severe Atopic Dermatitis from Previous Trials

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Major depression

Not recruiting

Testing Ulotaront Added to Antidepressants for Adults with Major Depressive Disorder Who Did Not Respond Well to Initial Treatment

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Citalopram
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

Rheumatoid arthritis

Not recruiting

Study on Burfiralimab for Patients with Moderate to Severe Rheumatoid Arthritis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Burfiralimab
  • Sponsor:Immunemed Inc.

Dermatitis atopic

Not recruiting

Study on Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis Using Topical Corticosteroids

Registered drug
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of XPro1595 for Patients with Early Alzheimer's Disease and Inflammation Markers

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Pegipanermin
  • Sponsor:Inmune Bio Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.